{"name":"Minneamrita Therapeutics LLC","slug":"minneamrita-therapeutics-llc","ticker":"","exchange":"","domain":"","description":"Minneamrita Therapeutics LLC is a biotechnology company focused on developing innovative treatments for cancer. The company's pipeline includes two drug candidates, both in Phase 1 clinical trials, aimed at addressing significant unmet medical needs.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxNZGtWZHFNbTBHS1YyTU1ENWd4Y09VQ3ZPbWQ2NmZyUHlVbl8zdU5JR1hwbl9aN2xQdlNHaWNSdWV4cjlOdEhHMGVSeEtkaWlVOFN5dGRZZHRHLUN4b1dBUmFGNGVIcWhTTi1NTnNnb00yUDlkLXRzTWVtTFZyT1ozbUtGTmxlUnZzZmEwQkZXSEVIXzR1VkxDWlluLVRXR0tDdTZteTQ0V2ZFbGM3TmJjVWM1TEI4MUlHWnRCOEwydmx6YUtreVMybWJoUWxkSkZtb3dYb1VJNjVLSTdFNWotdGY1ZnlxdnNRWkt1Q2VCeGVvbVpfUWptOXlISkhNZ01FQWF3Zks5YWVJQ0FVYkVpV2x1TnVTdVpK?oc=5","date":"2025-06-09","type":"regulatory","source":"PR Newswire","summary":"HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020-2034) | DelveInsight - PR Newswire","headline":"HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOalJtR2w0aVlVUFlGNlo5bEhmT1RxTmRmcm1FV1l0Z0dCQkVrSVN2aWo3dE1ERTBkR00zbzEwWUtGcjFiM2ZTc3NXeHBsbWZEYlU1Qk9QVXpvT21TMy10NlFiWnhXaTh5NXljeVJvalBmMkNBQXpfZzFUWHNJak1FLXlLZHptaGF2M2plZXQ3NjV3cjZLbmVhM3o1Q01CbXRiZFZQTm83Qlcyam93RnBJOFV4ZG9RU3cwZnJZTUhLejdNakZGbFZN?oc=5","date":"2024-10-01","type":"pipeline","source":"PR Newswire","summary":"PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight - PR Newswire","headline":"PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNaDNxcy0zZ285S0xJLUJMRTgwVmJFakViUXAtT1N2cjhDbm93TG9ZX3pGNmxnYngydWxnUjNDQWFFMk9ybHl2eVhPQWR6NDFuRWIwdUZwYW5OSzhDaVBESzJIMkZpMjRGU1MtWEdMN3JPQ0NYcU9hYlMzNGowdkNZbkFsZ3B5aVE?oc=5","date":"2023-02-02","type":"pipeline","source":"Brooklyn College","summary":"Presidential Lecture Series with Selwyn M. Vickers - Brooklyn College","headline":"Presidential Lecture Series with Selwyn M. Vickers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNbW1fbVU2N0ZFellXcTdaNmN0ajNTQ1VaYVBIOGhDWWxrdlhib1Z1YVd4YVNYQUVab0l0NU5PUWgyRVB5ekticWl5dDhGRk03NkxXbk5CUVN2WWNMWjNzZloxTXBCX1dTckpncGx4WVZRNUpHTzZEdGNhaWF1ZGRHeHZ0dmg5SVU?oc=5","date":"2022-09-19","type":"pipeline","source":"Memorial Sloan Kettering Cancer Center","summary":"President Selwyn M. Vickers - Memorial Sloan Kettering Cancer Center","headline":"President Selwyn M. Vickers","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}